9130で売り玉、マックス立てた 爆益中や、どあほ 0607山師さん＠トレード中2018/03/26(月) 14:48:36.32ID:lzZNOyxF ほー 0608山師さん＠トレード中 (ｻｻｸｯﾃﾛ Spbb-HRgT)2018/03/26(月) 15:05:54.67ID:9j7vwq8np ストップ高になったような気分だぜ 0609山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/26(月) 16:30:12.14ID:OGLh+GrJ0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ Heptares and Imperial seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target. Heptares is set to relocate to a new 35,000 sq ft facility at Granta Park, Cambridge in-mid 2018 by which time local headcount should be up to 130. Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018. Granta Park’s owner BioMed Realty: "The next move for Granta Park will be to welcome life science company Heptares in the summer." Heptares Zurich: For our branch in Schlieren, we are looking for an enthusiastic and motivated personality by the middle of 2018 as biology lab technician (70-100%). MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus. Pluristem: Our Expectations; Sosei CVC for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan. Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement. ペプチドリーム：Heptares戦略的提携、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告提供。 Novartis: Ultibro New Version of the Breezhaler Device (Concept2: Digital Adherence System). The First Clinical Study with this Inhaler is due to begin this Year. ・・・ 0610山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/26(月) 16:30:26.66ID:OGLh+GrJ0 ※Novartis Q1 2018 Results: (4/19) ※Pfizer Q1 2018 Earnings Release: (5/1) ※MorphoSys Q1 2018 Earnings Release. (5/3) ※あすか製薬 平成30年3月期決算発表: (5月上旬) ※Allergan Q1 2018 Earnings Release: (5/ ) ※Pluristem Q3 2018 Earnings Release: (5/ ) ※大日本住友製薬 2018年3月期決算発表: (5/11) ※明治ホールディングス 平成30年3月期決算発表: (5/11) ※第一三共2018年3月期決算発表: (5月中旬) ※SOSEI 平成30年3月期決算発表: (5月中旬) ※ペプチドリーム 平成30年6月期第3四半期決算発表: (5月中旬) ※AstraZeneca Q1 2018 Earnings Release: (5/18) ・・・ 0611山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/26(月) 16:30:55.83ID:OGLh+GrJ0 ※SOSEIの成長相場の動向： 2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ] 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ] 2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ] 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場] 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ] 2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移] 2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ] 2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移] 2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移] 2018/_3/16 (終値_9070) 売残高13500 買残高 2019900(+225500)※3/20up ・(3/5安値_8780)※[悪地合いにて再びの拾い場] 2018/_3/23 (終値_8590) 5日線乖離(-2.94%) 25日線乖離(-8.95％) 75日線乖離(-17.84％) 200日線乖離(-18.60％) (安値_8580) 2018/_3/26 (終値_8610) 5日線乖離(-1.69%) 25日線乖離(-8.23％) 75日線乖離(-17.41％) 200日線乖離(-18.30％) (安値_8320)
はじめて ノーポジ 株はそこ とっても きもちが いいもんだ 株価の うわねは おもいまま 株は ひどいぜ こころがしずむ からうり外資が てをふって ぼくの ろうばい ながめていたよ 0620山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/26(月) 21:00:14.14ID:OGLh+GrJ0 ※Pluristem: Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board. (3/26) Jeffs led United Therapeutics from its founding until 2016 and led Amgen’s Neupogen clinical programs. HAIFA, Israel, March 26, 2018 - Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Dr. Roger Jeffs has joined Pluristem’s strategic advisory board. Dr. Jeffs, a highly accomplished biopharma executive, will advise Pluristem on clinical and commercial strategies for the Company’s cell therapy programs. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as director of research, development, and medical and led the company as its President and CEO from 2001 to 2014 and President & co-CEO from 2015 to 2016. During hissuccessful 18-year tenure at United Therapeutics, Dr. Jeffs helped lead the company’s initial public offering, oversaw the clinical development and regulatory approval of six products, and managed the commercial effort that lead to a significant increase in revenues. Prior to his time at United Therapeutics, Dr. Jeffs was previously at Amgen Inc. where he helped lead the clinical program for Neupogen. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. He served on the Board of Directors for United Therapeutics from 2001 to 2016, and currently serves on the Boards of five public companies. Dr. Jeffs is also the co-founder and co-owner of Bull City Select Investments. Dr. Jeffs commented, “Pluristem’s placental cell therapies, currently being evaluated in multiple advanced clinical trials, could significantly advance regenerative medicine and make a change in the way patients are treated today, by delivering a safe and effective off-the-shelf cell therapy. The Company’s manufacturing assets are a key to its commercialization capabilities. I look forward to working with Pluristem’s management team to move the clinical programs forward towards marketing.” “Dr. Jeffs brings tremendous expertise and vision to Pluristem, from business aspects, to clinical development, marketing approval and commercialization. His work in developing Neupogen is directly relevant to our PLX-R18 clinical program in the treatment of bone marrow deficiencies,” stated Pluristem Chairman and Co-CEO Zami Aberman. “Pluristem is now forming a senior strategic advisory board in tpreparing the Company toward expansion and commercialization. We are honored and pleased that Dr. Jeffs is joining us at this important time.” 0621山師さん＠トレード中 (ﾜｯﾁｮｲ dfb4-fzSc)2018/03/26(月) 21:59:47.45ID:A97jRloI0>>616 今日も2枚買ったが明日も買うかもｗ 29日に一部売り抜ける予定ｗｗｗ 0622山師さん＠トレード中 (ﾜｯﾁｮｲW 5bfb-G2xb)2018/03/26(月) 22:31:26.41ID:9OptuDKH0>>616 yahoo板のkin＊＊＊さんに同意 0623山師さん＠トレード中 (ﾜｯﾁｮｲ dfb4-fzSc)2018/03/26(月) 23:19:30.94ID:A97jRloI0 ダウ暴騰やで 0624山師さん＠トレード中 (ﾜｯﾁｮｲW 376d-BHHQ)2018/03/26(月) 23:21:37.48ID:MRQUWL6V0>>623 日経先物弱いよ 今日20円上がったから明日はマイナス200かな？ 0625山師さん＠トレード中 (ｱｳｱｳｶｰ Sac3-vDKo)2018/03/26(月) 23:33:09.89ID:4DrnqH4Pa ダウが500位上がらんとだめかな こりゃ 0626山師さん＠トレード中 (ﾜｯﾁｮｲWW 5b97-DQlj)2018/03/27(火) 04:57:57.52ID:cJEWu2qY0 500上がったね 0627山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/27(火) 07:00:02.16ID:x+caHrRu0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018. Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility. ・・・ ※Nature Reviews: Fiona Marshall - co-founder of Heptares, a pioneer in structure-based drug design for GPCRs - the emerging therapeutic opportunities these targets offer. (3/1up) ※MiNA Therapeutics: Read about Our CEO Robert Habib in an Interview with OTS(Oligonucleotide Therapeutics Society). https://t.co/xRY7VsEQA9 (3/2) ※Business Weekly Cambridge: Granta Park’s owner BioMed Realty: "The next move for Granta Park will be to welcome life science company Heptares in the summer." (3/2) ※ClinicalTrial: Phase 2, Two Doses of QVM149 Compared to a Fixed Dose Combination of Sal/Flu in Patients With Asthma. Status Changed: "Recruiting", Actual Start: "2017/5/31", Completion: "2018/8/2". (3/2update) ※Heptares: Ali Jazayeri talk: Structural Elucidation of Class B G Protein-Coupled Receptors; Gordon Conference on Ligand Recognition and Molecular Gating; Ventura Beach; March 7. (3/2) ※Heptares: We are currently seeking a highly motivated and skilled organic chemist to join the Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position. "4/3 Closing" (3/2 Re-up) ※Heptares: We are growing our established Medicinal Chemistry Team and are seeking an enthusiastic and motivated Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. "4/3 Closing" (3/2 Re-up) ※C&EN: Why can’t the drug industry solve its gender diversity problem? Says Fiona Marshall, cofounder Heptares, "If good opportunities come that you want to do, you should grab them and then do a good job." (3/5) ※Metrion Biosciences (Granta Park): Announced it has appointed "Dr Barry Kenny (Non-Executive Director.)" to its Board of Directors. "Dr Kenny is Chief Business Officer of Heptares, now part of Sosei Group." (3/5) ※JITSUBO：インドNeulandとの包括的パートナーシップに向けた覚書締結。日本の先端技術とインドの高い製造能力・豊富な実績の国際連携で、大きなシナジーを創出できると確信しております。(3/5) ※Metrion Biosciences (Granta Park): Announced it has appointed "Dr Barry Kenny (Non-Executive Director.)" to its Board of Directors. "Dr Kenny is Chief Business Officer of Heptares, now part of Sosei Group." (3/5) ※米国特許(Heptares)：Muscarinic M1 Receptor Agonists. (3/6公開) ※ClinicalTrial: Phase 2, Two Doses of QVM149 Compared to a Fixed Dose Combination of Sal/Flu in Patients With Asthma. Patients who have used ICS and LABA combinations for asthma for at least "1 year"→"3 month". (3/6update) 👀 Rock54: Caution(BBR-MD5:b73a9cd27f0065c395082e3925dacf01) 0628山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/27(火) 07:00:26.61ID:x+caHrRu0 ※四季報Online：目先の利益の｢次｣が必要なバイオベンチャー、問われるのは､本当の開発力。今後、本当の意味での開発力が問われる局面に入っていく。いよいよ評価は正念場を迎えよう。(3/7) ※RCSB Protein Data Bank: "Crystal Structure of mGluR5 in complex: 6FFH, 6FFI." (Released 3/7) ※Nature.com: Oncogene: "Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer." (3/7) ※GRC Ligand Recognition and Molecular Gating: "GPCR-Mediated Signalling: Discussion Leader: Christopher Tate", "Structural Elucidation of Class B G Protein-Coupled Receptors": Ali Jazayeri. (3/7) ※ClinicalTrial: Phase 3, Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma. Changed: Study Start"2015/2/1"[Actual], Completion "2019/6/3"[Anticipated]. (3/7update) ※ClinicalTrial(Protocol: HTL0018318-202): A Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With AD. Actual Start: 2017/11/10. Estimated Completion: 2018/8. (3/7up) ※Heptares_HP: Press room Downloads page (3/8 Delete) ※MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus. (3/8) ※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease. (3/9) ※ClinicalTrial: Phase 3, A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma. Primary Completion[Anticipated]: 2018/11/6→"2018/9/18". (3/9update) ※ClinicalTrial: Phase 3, Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma. Status Changed:"Recruiting", Actual Study Start: "2018/2/9" (3/12update) ※SOSEI：片頭痛、その他重度の頭痛に対する治療薬である新規低分子CGRP拮抗薬のグローバルにおける開発・販売の権利をTeva社が返還。臨床開発の段階へ迅速に進められる状態にある。(3/13) ※Heptares: We are now recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group GPCR. (3/13 Closed) ※SOSEI個人投資家説明会(資料)：レビー小体型認知症を適用としたHTL001831の開発(日本)：ティム・タスカー、構造生物学及び研究開発パイプラインについて：マルコム・ウィアー。(3/14up) ※個別株情報：野村証券は業績予想下方修正。Teva社開発・販売マイルストーンが受け取れなくなる、自社での臨床試験が必要。HTL0022562を再導出すると見込、開発の遅れは見込まず、24年3月期の発売を予想。(3/14) ※ClinicalTrial: A Phase 1b, FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil±Memantine) for the Treatment of Participants With Mild to Moderate AD. Start Changed: 2/20→"2018/4/13". (3/14update) ※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14Closed) ※Heptares Zurich: We are looking for an enthusiastic and motivated personality by the middle of 2018 as " Biologielaborant Laboratory Technician, 70-100%". (3/14up) 0629山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/27(火) 07:00:48.07ID:x+caHrRu0 ※フィスコ：みずほ証券は説明会で今後2年で臨床入りさせる自社パイプラインについて、これまで開示された2つに加え4つのプログラムが明らかになり、ポテンシャル拡大を評価している。(3/15) ※個別株情報：いちよしが中長期利益予想を見直し。しばらく自社で開発を進め、より価値を高めた上で導出するなどの新たなシナリオも考えられるが、現時点では保守的に見るとした。(3/15) ※名古屋大学細胞生理学研究センター/株式会社CeSPIA：『Richard Henderson博士による講演会』："Electron cryomicroscopy in structural biology: progress and prospects." Richard Henderson. (3/16) ※四季報：研究開発費増勢で利益回復限定的。他社との提携・導出に加え、自社販売視野に入れた開発候補７品目保有。18年内にレビー小体型認知症薬は2相、神経性疾患薬は1相入り目指す。(3/16更新) ※米国特許出願(Heptares)：Spirocyclic Compounds as Agonists of the Muscarinic M1 Receptor and/or M4 Receptor. (3/15公開) ※Heptares: We are now seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. (3/15 Closed) ※SOSEI個人投資家説明会(動画)：http://www.sosei.com/ir/library/results_briefing.html (3/19up) ※Heptares: Jon Mason talk: Unmasking full GPCR ligand design for potency, selectivity and kinetics; ACS national meeting; New Orleans; March 21. (3/19) ※Imperial College London: We are seeking a Post-Doctoral Scientist "Research Associate" with a background in engineering or physical sciences. Heptares Partnership Project. (3/20up) ※The Cambridge Science Festival 2018: University of Cambridge: Cambridge Academy for Science and Technology: "Revealing the wonders of the molecular world": Richard Henderson. (3/20) ※ClinicalTrials: Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. Changed Study Completion: 2019/8/21→"2019/12/23"[Anticipated] (3/20update) ※ACS Symposium: "Unmasking full GPCR ligand design for potency, selectivity and kinetics from new and multiple ligand X-ray structures, water networks and GRID molecular interaction field analyses": Jon Mason. (3/21) ※Vectura 2017 Preliminary Results: Ultibro and Seebri, 2017 combined net sales of $562 million and Vectura recognised £17.3 million of Total Royalties for sales of these products. (3/21) ※Vectura Earnings Call: "Ultibro growing at almost 21% year-on-year.", "In our 2018 outlook strong growth of revenues driven by Ultibro in particular." (3/21) ※Biotech and Money: Biotechs and the City Spring 2018, London: Panel: "Changing trends in life science deals". Panellist: Malcolm Weir, Chairman and CEO, Heptares. (3/22) ※Heptares: We are now seeking to recruit an experienced Protein Biochemist for a One-Year Fixed term contract. 4/17 Closing (3/22) ※四季報Online：ベンチャーで承認申請が期待される新薬候補：既に承認申請済みの製品群では、そーせいグループの口腔咽頭カンジダ症治療薬「SO1105」が期待される。(3/24) ※BioCentury: Product Development: Optimism for A2A. Why Two Negative Readouts haven't Dimmed Hope for A2A in Cancer. (3/24) ※Heptares: We are growing our established Medicinal Chemistry Team and are seeking an enthusiastic and motivated Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. (4/3Closing→3/24Closed) ・・・ 0630山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/27(火) 07:01:35.06ID:x+caHrRu0 ※Sunovion: US, Utibron and Seebri Neohaler, Savings Card (Savings Program: Valid for up to $250 off. cost may be as little as a $0 co-pay. qualify for a 30-day trial offer). (Expiration Date: 2018/3/31.) ※Heptares: We are currently seeking a highly motivated and skilled organic chemist to join the Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position. (4/3 Closing) ※Heptares: We are now seeking to recruit a highly motivated "Analytical / Separation Scientist (Scientist/Research Scientist Grade)" GPCR. (4/3 Closing) ※CECAM Workshops: CompAllo: Towards a Unified Approach to the Analysis and Design of Allostery: Rob Cooke (invited speaker). (4/9-11) ※North American SMALP Conference: Overcoming Bottlenecks in Membrane Biology: "Structure-Based Drug Design of GPCRs": Jana Broecker. (4/11 14:10) ※UK-QSAR Group and Molecular Graphics and Modelling Society Joint Conference : "Beyond the Happy Water - recent advances in the quantification of contributions": Ben Tehan. (4/12 14:30) ※EASL(European Association for the Study of the Liver) International Liver Congress: MiNA Therapeutics. (4/15) ※Oxford Global Conferences, 5th Annual Peptides Congress: Cedric Fiez-Vandal, Senior Scientist, Heptares Therapeutics. (4/16-17) ※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17 Closing) ※Imperial College London: Seeking a Post-Doctoral Scientist with a background in engineering or physical sciences to develop and apply advanced contrast enhanced ultrasound imaging. (4/17 Closing) ※Heptares: We are now seeking to recruit an experienced Protein Biochemist for a One-Year Fixed term contract. (4/18 Closing) ※Novartis First Quarter Results 2018: (4/19) ※Heptares: By mid-2018, we are seeking for our site in Schlieren/Zurich (Switzerland) an enthusiastic and motivated laboratory technician (70-100%). (4/20 Closing) ※ASPET Annual Meeting at Experimental Biology 2018: "X-Ray Structures of GPCRs Provide Insights into New Binding Sites for Drug Discovery": Jon Mason. (4/24) ※Basel Area, Swiss Life Sciences Event: "Between Basic Research and Biotech Entrepreneurship": Andreas Pluckthun. (4/24 19:00) ・・・ 0631山師さん＠トレード中 (ﾜｯﾁｮｲ c78e-Zp0r)2018/03/27(火) 07:02:10.08ID:x+caHrRu0 ※SOSEIの成長相場の動向： 2010/12/30 (終値_1350) ・(2010/10/15※最安値_650、2010/12/27最高値_1748) 2011/12/30 (終値_1271) ・(2011/3/15※最安値__693、2011/6/30最高値_1680) 2012/12/28 (終値_2087) ・(2012/6/6※最安値__950、2012/9/7最高値_2967) 2013/12/30 (終値_4315) ・(2013/1/4※最安値_2050、2013/5/7最高値_6100) 2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ] 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ] 2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ] 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場] 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ] 2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移] 2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ] 2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移] 2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移] 2018/_3/16 (終値_9070) 売残高13500 買残高 2019900(+225500)※3/20up ・(3/5安値_8780)※[悪地合いにて再びの拾い場] 2018/_3/23 (終値_8590) 5日線乖離(-2.94%) 25日線乖離(-8.95％) 75日線乖離(-17.84％) 200日線乖離(-18.60％) (安値_8580) 2018/_3/26 (終値_8610) 5日線乖離(-1.69%) 25日線乖離(-8.23％) 75日線乖離(-17.41％) 200日線乖離(-18.30％) (安値_8320)
